FDA Brief

Warning letters Drugs

FDA warning letter to

Jeffrey W. Taub, M.D./Children's Hospital of Michigan

High riskIssued Dec 19, 2023Posted Jan 9, 2024Center for Drug Evaluation and Research | CDER

FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.

What happened

FDA inspected Dr. Taub's clinical site from September 23, 2022, to October 12, 2022, as part of its Bioresearch Monitoring Program. FDA found that a 6-year-old subject received three extra doses and three extra five-day cycles of study drugs, and that study drug was dispensed and blood and bone marrow samples were collected while institutional review board (IRB) approval had lapsed from January 14, 2022, to January 24, 2022. FDA reviewed the site's October 27, 2022, and January 10, 2023, responses to the Form FDA 483 inspection observations and found the corrective action plans lacked sufficient detail.

What FDA found

  1. The investigator did not make sure the study followed the investigational plan; a 6-year-old subject received three extra doses and three extra five-day cycles of study drugs, increasing risk of serious nerve and blood toxicities.

    21 CFR 312.60
  2. The investigator did not make sure a compliant institutional review board (IRB) reviewed and approved the study continuously; IRB approval lapsed from January 14 to January 24, 2022, while study drug was dispensed and blood and bone marrow samples were collected.

    21 CFR 312.66

What FDA wants

Within 15 business days of receiving the letter, Dr. Taub must write to FDA describing actions taken to prevent similar violations. FDA also asks for follow-up documentation on site policies and procedures for protocol compliance, randomization assignments, and timely IRB continuing review.

Who should pay attention

  • clinical investigators running pediatric oncology trials
  • IRBs and research sites overseeing human-subject studies
  • sponsors and contract research organizations monitoring protocol and IRB compliance

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  3. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk
  4. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk